Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115251) titled 'The Study on the Mechanism of Osimertinib-induced Pulmonary Toxicity through Up-regulating TRAPPC9 in Lung Epithelial Cells to Activate Secretory Autophagy and Recruit Macrophages' on Dec. 24, 2025.
Study Type: Observational study
Study Design:
Case-Control study
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Thoracic tumor/non-small cell lung cancer
Intervention:
Case Group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-25
Target Sample Size: Case Group:50;Control group:50;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/s...